TY - JOUR
T1 - In vivo pathway of thermal hyperalgesia by intrathecal administration of α,β-methylene ATP in mouse spinal cord
T2 - Involvement of the glutamate-NMDA receptor system
AU - Tsuda, Makoto
AU - Ueno, Shinya
AU - Inoue, Kazuhide
PY - 1999
Y1 - 1999
N2 - 1. The aim of the present study is to characterize the role of the P2X receptor in spinal nociceptive processing in vivo. We investigated the mechanisms of the P2X receptor agonist α,β-methylene ATP (α,βmeATP)-induced modulation of acute nociceptive signalling in mouse spinal cord. 2. Intrathecal administration of α,βmeATP produced a significant and dose-dependent thermal hyperalgesic response. This response was completely blocked by intrathecal pretreatment with the non-selective P2 receptor antagonist, pyridoxal-phosphate-6-azophenyl-2',4'-disulphonate (PPADS) and the selective P2X1, P2X3 and P2X2+3 receptor antagonist, 2',3'-O-(2,4,6-trinitrophenyl)adenosine 5'-triphosphate (TNP-ATP). Pretreatment with α,βmeATP 15, 30 and 60 min prior to administration of a second dose of α,βmeATP diminished the α,βmeATP-induced thermal hyperalgesia. 3. A potent agonist for the P2X1 receptor, β,γ-methylene-L-ATP, did not show the hyperalgesic response, indicating that the P2X1 receptor is not involved in the spinal nociceptive pathway. 4. In fura-2 experiments using mouse dorsal root ganglion (DRG) neurons, α,βmeATP (100 μM) increased intracellular Ca2+ ([Ca2+](i)). This was not produced by a second application of α,βmeATP. The same DRG neurons also showed a marked [Ca2+](i) increase in response to capsaicin (3 μM). 5. Intrathecal pretreatment with the Ca2+-dependent exocytosis inhibitor, botulinum neurotoxin B, abolished the thermal hyperalgesia by α,βmeATP. Furthermore, thermal hyperalgesia was significantly inhibited by the N-methyl-D-aspartate (NMDA) receptor antagonists, 2-amino-5-phosphonopentanoate (APV), dizocilpine and ifenprodil. 6. These findings suggest that α,βmeATP-induced thermal hyperalgesia may be mediated by the spinal P2X3 receptor subtype that causes unresponsiveness by repetitive agonist applications, and that α,βmeATP (perhaps through P2X3 receptors) may evoke spinal glutamate release which, in turn, leads to the generation of thermal hyperalgesia via activation of NMDA receptors.
AB - 1. The aim of the present study is to characterize the role of the P2X receptor in spinal nociceptive processing in vivo. We investigated the mechanisms of the P2X receptor agonist α,β-methylene ATP (α,βmeATP)-induced modulation of acute nociceptive signalling in mouse spinal cord. 2. Intrathecal administration of α,βmeATP produced a significant and dose-dependent thermal hyperalgesic response. This response was completely blocked by intrathecal pretreatment with the non-selective P2 receptor antagonist, pyridoxal-phosphate-6-azophenyl-2',4'-disulphonate (PPADS) and the selective P2X1, P2X3 and P2X2+3 receptor antagonist, 2',3'-O-(2,4,6-trinitrophenyl)adenosine 5'-triphosphate (TNP-ATP). Pretreatment with α,βmeATP 15, 30 and 60 min prior to administration of a second dose of α,βmeATP diminished the α,βmeATP-induced thermal hyperalgesia. 3. A potent agonist for the P2X1 receptor, β,γ-methylene-L-ATP, did not show the hyperalgesic response, indicating that the P2X1 receptor is not involved in the spinal nociceptive pathway. 4. In fura-2 experiments using mouse dorsal root ganglion (DRG) neurons, α,βmeATP (100 μM) increased intracellular Ca2+ ([Ca2+](i)). This was not produced by a second application of α,βmeATP. The same DRG neurons also showed a marked [Ca2+](i) increase in response to capsaicin (3 μM). 5. Intrathecal pretreatment with the Ca2+-dependent exocytosis inhibitor, botulinum neurotoxin B, abolished the thermal hyperalgesia by α,βmeATP. Furthermore, thermal hyperalgesia was significantly inhibited by the N-methyl-D-aspartate (NMDA) receptor antagonists, 2-amino-5-phosphonopentanoate (APV), dizocilpine and ifenprodil. 6. These findings suggest that α,βmeATP-induced thermal hyperalgesia may be mediated by the spinal P2X3 receptor subtype that causes unresponsiveness by repetitive agonist applications, and that α,βmeATP (perhaps through P2X3 receptors) may evoke spinal glutamate release which, in turn, leads to the generation of thermal hyperalgesia via activation of NMDA receptors.
UR - http://www.scopus.com/inward/record.url?scp=0033036741&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033036741&partnerID=8YFLogxK
U2 - 10.1038/sj.bjp.0702582
DO - 10.1038/sj.bjp.0702582
M3 - Article
C2 - 10385245
AN - SCOPUS:0033036741
SN - 0007-1188
VL - 127
SP - 449
EP - 456
JO - British Journal of Pharmacology
JF - British Journal of Pharmacology
IS - 2
ER -